Browse

Capecitabine for the treatment of gastric cancer

Cited 10 time in Web of Science Cited 10 time in Scopus
Issue Date
2015-12
Citation
Expert Review of Gastroenterology and Hepatology, Vol.9 No.12, pp.1471-1481
Keywords
5-fluorouraciladjuvantcapecitabinechemotherapygastric cancerpalliative
Abstract
Capecitabine is an orally administered prodrug of 5-fluorouracil (5-FU) and was designed to specifically affect tumor cells more than normal tissues. Capecitabine is as effective and well tolerated as infusional 5-FU in the treatment of advanced gastric cancer (AGC). Following the REAL-2 and ML17032 studies, capecitabine has replaced infusional 5-FU for treating GC. Capecitabine plus platinum is one of the most widely used regimens for the first-line treatment of AGC, regardless of HER2 status. The adjuvant capecitabine/oxaliplatin regimen is one therapeutic option for resectable gastric cancer, especially after D2 resection. Compared with S-1, capecitabine has been shown to have a similar efficacy, but is associated with fewer ethnic differences than S-1, which accounts for the more widespread usage of capecitabine worldwide.
ISSN
1747-4124
URI
https://hdl.handle.net/10371/173071
DOI
https://doi.org/10.1586/17474124.2015.1096774
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse